Forte Biosciences Announces $150 Million Public Offering and Strategic Investment from argenx BV

On April 8, 2026, Forte Biosciences, Inc. (FBRX) entered into an underwriting agreement with Guggenheim Securities, LLC to issue and sell 5,709,936 shares of common stock in a public offering at a price of $26.27 per share. The company also granted underwriters a 30-day option to purchase up to an additional 856,490 shares. Gross proceeds are expected to be approximately $150 million, with net proceeds estimated at $141 million (or $162 million if the over-allotment option is fully exercised). Notably, argenx BV has made a strategic investment in the company as part of this offering. The transaction is expected to close on or about April 10, 2026, subject to customary closing conditions. The company intends to use the proceeds for general corporate purposes. The offering is conducted under an existing shelf registration statement on Form S-3.